The vaccine aided BioNTech’s sales to boom, hitting $8.7 billion in total revenues in the first 6 months of 2021, from $82.1 million for the year-ago period.
"The increase was mainly due to rapid increases in the supply of COVID-19 vaccine worldwide,” said the company in a statement last month. BioNTech has turned to profits, thanks to the vaccine, with $4.6 billion in the first six months of the year, compared to nearly $168 million net loss for the same period a year ago.
The company, which recorded $8.6 billion in vaccine sales in the first half, said that estimated COVID-19 vaccine revenues for the 2021 financial year - upon delivery of currently signed supply contracts of 2.2 billion doses as of July 21, 2021 - is $18.8 billion.
BioNTech and Pfizer expect BNT162b2 annual manufacturing capacity to reach three billion doses by the end of the year and expect to have the capacity to manufacture up to four billion doses in 2022. The vaccine has led Uğur Şahin the CEO and co-founder of German biotech firm BioNTech, to join the billionaire club with a net worth of $13.2 billion as of September 9, 2021. Source: Forbes ME
